Abstract
Sch 56592 is a new triazole agent with potent, broad-spectrum antifungal activity. The in vitro activities of Sch 56592, itraconazole, fluconazole, amphotericin B, and flucytosine (5-FC) against 404 clinical isolates of Candida spp. (382 isolates) and Saccharomyces cerevisiae (22 isolates) were investigated. In vitro susceptibility testing was performed by a broth microdilution method performed according to National Committee for Clinical Laboratory Standards guidelines. Overall, Sch 56592 was very active (MIC at which 90% of isolates are inhibited [MIC90], 0.5 microgram/ml) against these yeast isolates. Sch 56592 was most active against Candida tropicalis, Candida parapsilosis, candida lusitaniae, and Candida stellatoidea (MIC90, < or = 0.12 microgram/ml) and was least active against Candida glabrata (MIC90, 2.0 micrograms/ml). Sch 56592 was 2- to 32-fold more active than amphotericin B and 5-FC against all species except C. glabrata. By comparison with the other triazoles, Sch 56592 was equivalent to itraconazole and greater than or equal to eightfold more active than fluconazole. On the basis of these results, Sch 56592 has promising antifungal activity, and further in vitro and in vivo investigations are warranted.
Full Text
The Full Text of this article is available as a PDF (205.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Galgiani J. N., Lewis M. L. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1997 Jan;41(1):180–183. doi: 10.1128/aac.41.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perfect J. R., Cox G. M., Dodge R. K., Schell W. A. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996 Aug;40(8):1910–1913. doi: 10.1128/aac.40.8.1910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J. H., Rinaldi M. G., Cooper C. R., McGinnis M. R. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995 May;33(5):1104–1107. doi: 10.1128/jcm.33.5.1104-1107.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rex J. H., Pfaller M. A., Lancaster M., Odds F. C., Bolmström A., Rinaldi M. G. Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol. 1996 Apr;34(4):816–817. doi: 10.1128/jcm.34.4.816-817.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sugar A. M., Liu X. P. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother. 1996 May;40(5):1314–1316. doi: 10.1128/aac.40.5.1314. [DOI] [PMC free article] [PubMed] [Google Scholar]